(4-chloro-5-methoxy-[1,10]phenanthrolin-2-yl)methanol | 1228760-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 菲咯啉
• 英文名称: (4-chloro-5-methoxy-[1,10]phenanthrolin-2-yl)methanol
• 英文别名: (4-Chloro-5-methoxy-[1,10]phenanthrolin-2-yl)-methanol；(4-chloro-5-methoxy-1,10-phenanthrolin-2-yl)methanol
• CAS: 1228760-69-7
• 化学式: C₁₄H₁₁ClN₂O₂
• 分子量: 274.707
• InChiKey: FHLGIXQIZBNDCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  55.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  硼氢化钠 、 4-chloro-5-methoxy-[1,10]phenanthroline-2-carboxylic acid methyl ester 在 二氯甲烷 、 水 、 Brine 、 Sodium sulfate-III 作用下， 以 methanol-dichloromethane 为溶剂， 反应 19.0h， 以to afford pure alcohol 66 (710 mg 78%) as a brown solid的产率得到(4-chloro-5-methoxy-[1,10]phenanthrolin-2-yl)methanol
  参考文献：
  名称：

  TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER

  摘要：

  本发明涉及一种新的三取代苯并二氮杂菲衍生物家族，其化学式为(I)，可用于治疗或预防神经退行性或血液疾病或状况或癌症，它们作为药物的用途，特别是用于治疗神经退行性或血液疾病或状况或癌症，以及包含这些化合物的制药组合物。

  公开号：

  US20110306631A1

文献信息

• Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions
  申请人：NOSCIRA, S.A.

  公开号：EP2196466A1

  公开（公告）日：2010-06-16

  The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.

  本发明涉及一种新的式（I）三取代苯并脯氨酸衍生物家族，它们可用于治疗或缓解神经退行性疾病或血液病，也可用作药物，特别是用于治疗神经退行性疾病或血液病，还涉及一种包含这些化合物的药物组合物。
• [EN] TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER<br/>[FR] DÉRIVÉS DE LA PHÉNANTHROLINE À TRIPLE SUBSTITUTION POUR LE TRAITEMENT DE MALADIES OU CONDITIONS NEURODÉGÉNÉRATIVES OU HÉMATOLOGIQUES, OU DU CANCER
  申请人：NOSCIRA SA

  公开号：WO2010066832A1

  公开（公告）日：2010-06-17

  The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition or cancer, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition or cancer, and a pharmaceutical composition comprising the compounds.
• TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER
  申请人：Medina Padilla Miguel

  公开号：US20110306631A1

  公开（公告）日：2011-12-15

  The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition or cancer, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition or cancer, and a pharmaceutical composition comprising the compounds.

  本发明涉及一种新的三取代苯并二氮杂菲衍生物家族，其化学式为(I)，可用于治疗或预防神经退行性或血液疾病或状况或癌症，它们作为药物的用途，特别是用于治疗神经退行性或血液疾病或状况或癌症，以及包含这些化合物的制药组合物。